<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508907</url>
  </required_header>
  <id_info>
    <org_study_id>20-001964</org_study_id>
    <nct_id>NCT04508907</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients</brief_title>
  <official_title>Pilot Study for the Use of Shortened Preemptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney, Heart, Lung and/or Pancreas) of Hepatitis C Viremic Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine the effectiveness of using a combination of two&#xD;
      different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV&#xD;
      negative solid organ recipient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of prevention of HCV viremia in recipients of HCV viremic solid organs</measure>
    <time_frame>3 months</time_frame>
    <description>The study will assess the percentage of patient who will not become HCV viremic using this preemptive treatment protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft and patient survival</measure>
    <time_frame>1 year</time_frame>
    <description>Study will assess the overall 1 year patient and graft survival.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Heart Transplant Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1: Pre-emptive Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study were all recipients of HCV viremic organs will receive combination therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavyret</intervention_name>
    <description>Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients</description>
    <arm_group_label>Arm 1: Pre-emptive Treatment Arm</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Listed kidney, heart, lung and/or pancreas patients who are negative for chronic&#xD;
             hepatitis C infection&#xD;
&#xD;
          -  Willing to accept and consent for accepting hepatitis C positive graft&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Existing chronic liver disease (liver cirrhosis)&#xD;
&#xD;
          -  Concomitant infection with HIV or Chronic hepatitis B&#xD;
&#xD;
          -  Patient or any member of patient family or care giver team who does not understand or&#xD;
             accept the risk of an acquired HCV infection&#xD;
&#xD;
          -  Pregnancy (Pregnant patients do not undergo solid organ transplants)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bashar A Aqel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bashar Aqel</last_name>
    <phone>4803420272</phone>
    <email>aqel.bashar@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rolland Dickson</last_name>
    <phone>4803420274</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bashar Aqel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

